No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
CNMD240517C160000
- 0.75
- 0.000.00%
15min DelayClose May 8 15:59 ET
0.00High0.00Low
0.75Open0.75Pre Close0 Volume1 Open Interest160.00Strike Price0.00Turnover305.58%IV131.63%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.75Time Value100Contract SizeAmericanOptions Type0.0626Delta0.0038Gamma92.53Leverage Ratio-0.2176Theta0.0009Rho5.79Eff Leverage0.0132Vega
Intraday
- 5D
- 1D
News
ConMed(CNMD.US) Director Buys US$141.96K in Common Stock
$ConMed(CNMD.US)$ Director Aronson Martha Goldberg purchased 2,000 shares of common stock on May 6, 2024 at an average price of $70.98 for a total value of $141.96K.Source: Announcement What is statem
An Intrinsic Calculation For CONMED Corporation (NYSE:CNMD) Suggests It's 50% Undervalued
Key Insights CONMED's estimated fair value is US$141 based on 2 Stage Free Cash Flow to Equity CONMED's US$70.75 share price signals that it might be 50% undervalued Analyst price target for CNMD
Express News | Needham Reiterates Buy on Conmed, Maintains $107 Price Target
Conmed's Resilience Justifies Buy Rating Amid New Market Challenges
$1M Bet On Skyworks Solutions? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the st
Insider Buying Alert: COO Pat Beyer Acquires Shares of Conmed Corp (CNMD)
Comments
CONMED's ROE is deemed 'sub-optimal'. The business isn't thrilling as it uses high debt to boost sub-par returns. Theoretically, greater ROE could improve through leverage, but higher debt presents greater risk.
CONMED's stock appears overpriced when gauged against the industry average PE ratio. Despite its positive outlook being factored into its valuation, the elevated price could present a risk to potential sellers and isn't the optimum entry point for potential investors.
CONMED's move to profitability is typically seen as a good sign but investor sentiment may be changing due to recent share price drop. The company exhibits two cautionary signs for investors.
Gainers:
• $Victoria's Secret(VSCO.US$ +10.4% (In reaction to earnings)
• $Salesforce(CRM.US$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo(WB.US$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US$ +3.1% (Late-Breaking Presentations of P...
• $Victoria's Secret(VSCO.US$ +10.4% (In reaction to earnings)
• $Salesforce(CRM.US$ +9.0% (In reaction to earnings)
• $Navigator(NVGS.US$ +4.9% (names Mads Peter Zacho as CEO)
• $Weibo(WB.US$ +4.7% (In reaction to earnings)
• $CAE Inc(CAE.US$ +4.7% (In reaction to earnings)
• $Laredo Petroleum(LPI.US$ +4% (authorized $200 mln share repurchase program)
• $Axsome Therapeutics(AXSM.US$ +3.1% (Late-Breaking Presentations of P...
21
Read more
wooperOP : FYI is just getting started will run all day